A strategy to boost the immune response to vaccination in patients with seropositive rheumatoid arthritis.
Reference1. Colmegna I, Useche M, Rodriguez K, et al. Efficacy of High-Dose Versus Standard-Dose Influenza Vaccine in Seropositive Rheumatoid Arthritis Patients [Abstract 837]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 31, 2018.This information is brought to you by Rheumatology Network and is not sponsored by, nor a part of, the American College of Rheumatology.
Colmegna and colleagues in Canada found that high-dose trivalent inactivated influenza vaccine (HD-TIV) substantially improves the immune response in patients with seropositive rheumatoid arthritis (RA) when compared with the standard-dose quadrivalent inactivated influenza vaccine (SD-QIV).1 The authors presented their findings at the recent American College of Rheumatology (ACR 2018) annual meeting in Chicago, IL. Scroll through the slides for the details of their study and the take-home points for clinicians.
DMARD, disease-modifying antirheumatic drug; HD-TIV, high-dose trivalent inactivated influenza vaccine; RA, rheumatoid arthritis; SD-QIV, standard-dose quadrivalent inactivated influenza vaccine.
Vaccine strains were A/HongKong/4801/2014(H3N2), B/Brisbane/60/2008 in Y1/2, with A/California/7/2009(H1N1) in Y1 and A/Michigan/45/2015(H1N1) in Y2.
CI, confidence interval; HD-TIV, high-dose trivalent inactivated influenza vaccine; SD-QIV, standard-dose quadrivalent inactivated influenza vaccine.